Randomized study for treatment of COVID pneumonia uses cystic fibrosis drug dornase alfa

Randomized study for treatment of COVID pneumonia uses cystic fibrosis drug dornase alfa
Researchers at Boston Children's Hospital and Brigham and Women's Hospital have launched a randomized, placebo-controlled clinical trial of dornase alfa (Pulmozyme) in patients with severe COVID-19 pneumonia and respiratory failure requiring mechanical ventilation. The study aims to enroll 60 adults and children (over age 3) admitted to intensive care units.